<DOC>
	<DOCNO>NCT02271139</DOCNO>
	<brief_summary>This open-label , multicenter , single-arm , expand access study design provide alectinib participant ALK-rearranged NSCLC disease progression intolerance prior ALK tyrosine kinase inhibitor ( TKI ) therapy . Participants receive alectinib disease progression , unacceptable toxicity , withdrawal consent , patient physician decision discontinue treatment , death , alectinib becomes commercially available United States follow approval alectinib FDA , Sponsor decide close trial , whichever occur first ( approximately 15 month ) .</brief_summary>
	<brief_title>Expanded Access Study Alectinib Participants With Anaplastic Lymphoma Kinase ( ALK ) -Rearranged Non-Small Cell Lung Cancer ( NSCLC ) After Disease Progression Intolerance Prior ALK Tyrosine Kinase Inhibitor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Participants locally advance ( American Joint Committee Cancer [ AJCC ] Stage IIIB ) amenable curative therapy metastatic ( AJCC Stage IV ) NSCLC Life expectancy least 12 week Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 03 Histologically confirm NSCLC Documented ALK rearrangement assess approve fluorescence situ hybridization ( FISH ) test , use Vysis ALK Break Apart FISH Probe Kit Ventana immunohistochemistry ( IHC ) test After disease progression intolerance prior ALK TKI therapy : 1 ) participant need minimum washout period least 5 halflives last dose ALK TKI therapy target therapy first dose study treatment ; 2 ) participant must recover treatment toxicity less equal ( &lt; /= ) Grade 1 pretreatment level ( participant develop interstitial lung disease [ ILD ] , must fully recover ) ; 3 ) participant either chemotherapyna√Øve receive least one line platinumbased chemotherapy locally advance metastatic disease Recovery effect major surgery significant traumatic injury least 28 day first dose study treatment Adequate hematological renal function Agreement use highly effective method contraception per protocol definition Prior therapy alectinib Participants symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid within 1 week prior Day 1 manage CNS symptom Administration strong/potent cytochrome P450 3A ( CYP3A ) inhibitor inducer , agent potential QT prolonging effect within 14 day prior first administration study drug Participants liver disease Any clinically significant concomitant disease condition could interfere conduct study Active uncontrolled infectious disease require treatment History organ transplant Participants baseline QTc &gt; 470 millisecond ( m ) participant symptomatic bradycardia Pregnant lactating , intend become pregnant study History hypersensitivity additives alectinib formulation Any psychological , familial , sociological , geographical condition potentially hamper compliance study protocol requirement and/or followup procedure ; condition discuss participant trial entry Serious , uncontrolled infection current know infection human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>